BioSpace News Archive

Deals

Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO

Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.

January 13, 2021
·
3 min read
·
Brandon May
Business

Takeda Operations Heat Up with New Research Partnerships and Acquisitions

Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception.

January 13, 2021
·
3 min read
·
Brandon May
Drug Development

COVAXX CEO Works to Redefine the Idea of a Vaccine

The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.

January 13, 2021
·
5 min read
·
Heather McKenzie
Business

Bayer Continues Eying Potential Partnerships in Cell and Gene Therapy Space

In an interview with BioSpace, Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space.

January 13, 2021
·
4 min read
·
Alex Keown
Business

Amgen Inks $240 Million Autoimmune Deal with Tiny EVOQ Therapeutics

The two companies will work together to use dendritic cells to develop immune tolerance.

January 13, 2021
·
2 min read
·
Mark Terry
Drug Development

JPM2021, Day 2: Gilead, Merck, AbbVie, Pfizer and More

As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.

January 13, 2021
·
5 min read
·
Mark Terry
Business

Flagship Pioneering Launches Company to Explore New Biological Pathway

Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.

January 13, 2021
·
3 min read
·
Alex Keown
Policy

Merck Receives Priority on Pneumococcal Vaccine, Offers Reassurance on Keytruda

Merck announced the U.S. Food and Drug Administration (FDA) had accepted its Biologics License Application (BLA) for V114, its 15-valent pneumococcal conjugate vaccine, for Priority Review.

January 13, 2021
·
3 min read
·
Mark Terry
Pharm Country

Pfizer Growth Initiative Invests $120 Million into Four Companies

Pfizer anticipates the initiative to invest up to half-a-billion dollars in small- to medium-sized companies developing clinical-stage assets aligned with Pfizer’s core areas of focus.

January 13, 2021
·
3 min read
·
Alex Keown
BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

January 13, 2021
·
9 min read
·
Alex Keown